Wockhardt Limited (NSE:WOCKPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 266.10B +33.1% |
| Revenue (ttm) | 33.73B +11.1% |
| Net Income | 2.13B |
| EPS | 13.10 |
| Shares Out | 162.49M |
| PE Ratio | 125.01 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,550,149 |
| Average Volume | 2,981,911 |
| Open | 1,591.60 |
| Previous Close | 1,575.40 |
| Day's Range | 1,571.00 - 1,645.00 |
| 52-Week Range | 1,086.70 - 1,868.80 |
| Beta | 0.77 |
| RSI | 62.44 |
| Earnings Date | May 4, 2026 |
About Wockhardt
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an anti... [Read more]
Financial Performance
Financial StatementsNews
Pharma Stocks Today, May 13: Wockhardt rises 1.97%, Orchid Pharma falls 1.79%, Biocon gains 1.38%
Indian pharmaceutical stocks showed a mixed trend on May 13 2026 during the early morning trading session. The BSE Healthcare index remained nearly flat, rising marginally by 0.04% to 46,087.93.…
Top losers today: godrej consumer products at ₹1,036.60 down 5.26%, wockhardt at ₹1,637.50 falls 4.62%, brigade enterprises at ₹773.15 slips 4.43%
The Indian stock market experienced a slight downturn today, with the SENSEX closing at 77,844.52, down by 0.15%, and the NIFTY 50 at 24,326.65, a marginal decrease of 0.02%. Among…
Top losers in morning trade: godrej consumer products at ₹1,043.40 down 4.63%, KPIT technologies at ₹715.00 falls 4.49%, wockhardt at ₹1,643.50 slips 4.28%
In the morning session of the Indian stock market, the SENSEX and NIFTY 50 indices showed slight declines, with the SENSEX at 77,842.60, down 0.15%, and the NIFTY 50 at…
Pharma sector stocks today, May 7: Wockhardt falls 4%, Panacea Biotec jumps 2.16%, Biocon up 1%
Pharma sector performance remained largely stable in early trading on May 7, 2026. The NIFTY PHARMA Index stood at 24,108.9, showing no change (down 0.0%). The broader S&P BSE HEALTHCARE…
Top gainers in morning trade: wockhardt at ₹1,731.30 up 12.64%, tejas networks at ₹477.80 up 12.27%, coforge at ₹1,272.50 up 8.87%
The Indian stock market opened on a positive note today, buoyed by favourable global cues and a decline in global crude prices. The Nifty 50 surged past the 24,100 mark,…
Pharma sector stocks rises today, May 6: Wockhardt jumps 7.16%, Ajanta Pharma surges 3.56%, Lupin up 1.60%
Indian pharmaceutical stocks traded higher in the early session on May 6, 2026. The Nifty Pharma index stood at 23,732.2, up 0.7%. The broader market also showed modest gains, with…
Top gainers in morning trade: wockhardt at ₹1,567.70 up 10.01%, quess corp at ₹229.50 up 8.44%, Tata technologies at ₹636.95 up 7.77%
Indian equity markets opened to a challenging session as geopolitical tensions weighed heavily on investor sentiment. Despite the broader market downturn, with the Sensex falling over 300 points and t...
Pharma sector stocks today, May 5: Wockhardt surges over 8%, Strides Pharma rises 1.81%, Natco Pharma up 1.36%
India's pharmaceutical sector showed a mixed opening on May 5, 2026, with the S&P BSE Healthcare index trading at 45,222.25, down 0.10% in early trade. While most pharma counters were…
Why are Wockhardt share price up over 10% today? Explained
Wockhardt shares rallied more than 10% in early trade on May 5, 2026, after the pharmaceutical company reported a sharp turnaround in its March quarter (Q4FY26) earnings. The company posted…
Wockhardt reports Rs 238 crore profit before tax for FY26
Wockhardt Limited, the pharmaceutical and biotechnology major, has reported a significant turnaround in its financial performance for the fiscal year 2025-26. The company achieved a profit before tax ...
Wockhardt Quarterly report: Q4 2026
Wockhardt has published its Q4 2026 quarterly earnings report on May 4, 2026.
Pharma sector stocks today, April 21: Wockhardt surge 2.08%, Natco Pharma down 1.86%, Ajanta Pharma up 1.10%
The Indian pharma sector opened on a mixed note on April 21, 2026 (as of 9:43 AM). The S&P BSE Healthcare Index stood at 43,475.50, up 0.23%, while the NIFTY…
Pharma sector stocks today, March 30: Suven Life surge 7.88%, Wockhardt up 3.27%, Gland Pharma falls 2.36%
As of approximately 9:33 AM IST on March 30, 2026 (BSE prices) and 9:34 AM IST (NSE prices), most pharma sector stocks on the BSE and NSE were trading in…
Wockhardt shares surge 3% after positive CDSCO panel nod for new antibiotic Zaynich
Shares of Wockhardt gained around 3% after the company announced that its novel antibiotic, Zaynich® (Zidebactam/Cefepime), received a favourable recommendation from the Subject Expert Committee (SEC)...
Pharma sector stocks today, March 25: Wockhardt surge 7.40%, Senores Pharma up 5.95%, Natco Pharma jumps 3.32%
Several pharmaceutical stocks traded higher in early morning sessions on the BSE and NSE. The S&P BSE Healthcare Index stood at 42,461.1, reflecting a gain of 1.4% for the day.…
Pharma sector stocks rally sharply today, March 25: Wockhardt surge 7.40%, Senores Pharma up 5.95%, Natco Pharma jumps 3.32%
Several pharmaceutical stocks traded higher in early morning sessions on the BSE and NSE. The S&P BSE Healthcare Index stood at 42,461.1, reflecting a gain of 1.4% for the day.…
Pharma sector stocks today, March 6: Shilpa Medicare surge 3.08%, Wockhardt jumps 2.12%, Natco Pharma up 1.84%,
The pharmaceutical sector in India showed mixed performance on March 6, 2026, during early trading hours. Data from around 9:46 AM to 9:50 AM IST indicated the S&P BSE HEALTHCARE…
Wockhardt Quarterly report: Q3 2026
Wockhardt has published its Q3 2026 quarterly earnings report on February 10, 2026.
Wockhardt shares in focus after Phase 3 success of novel antibiotic Foviscu
Shares of Wockhardt are likely to be in focus after the company announced positive results from a pivotal Phase 3...
Wockhardt files Marketing Authorisation Application to EMA for antibiotic WCK 5222
Wockhardt has taken a significant step in global pharmaceutical innovation by successfully filing a Marketing Authorisation Application (MAA) with the...
Wockhardt shares in spotlight after EMA grants accelerated assessment to WCK 5222
Shares of Wockhardt are likely to remain in focus on Wednesday, December 31, after the company announced that the European...
Wockhardt shares rally sharply over 9% as US FDA accepts NDA for breakthrough antibiotic Zaynich
Wockhardt Ltd. recorded a sharp rally of more than 9% after announcing a significant regulatory breakthrough: the United States Food...
Wockhardt secures historic US FDA acceptance for antibiotic Zaynich
Wockhardt Ltd. has achieved a historic milestone with the United States Food and Drug Administration formally accepting the New Drug...
Wockhardt Quarterly report: Q2 2026
Wockhardt has published its Q2 2026 quarterly earnings report on November 3, 2025.
Wockhardt submits NDA to US FDA for novel antibacterial Zidebactam-Cefepime
Wockhardt Ltd. has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (US FDA) for its novel antibacterial agent, Zidebactam-Cefepime injection (WCK 5222...